Profiel
Jon Weidanz was the founder of MHC Biologics LLC (founded in 2007) and Receptor Logic, Inc. (founded in 2003) where he held the title of Chief Scientific Officer.
He is also the founder of Abexxa Biologics, Inc. (founded in 2015) where he currently holds the title of Chief Scientific Officer.
Dr. Weidanz's former jobs include working as an Assistant Professor at Texas Tech University and as a Research Scientist at Baxter Diagnostics, Inc. Dr. Weidanz's education history includes an undergraduate degree from West Virginia University in 1985, a graduate degree from The University of Alabama at Birmingham in 1987, and a doctorate degree from The University of Alabama at Birmingham in 1992.
Dr. Weidanz is also the founder of Sunol Molecular Corp...
Actieve functies van Jon Weidanz
| Bedrijven | Functie | Begin |
|---|---|---|
Abexxa Biologics, Inc.
 Abexxa Biologics, Inc. Pharmaceuticals: MajorHealth Technology AbeXXa Biologics, Inc. is engaged in biopharmaceutical services. The company was founded by Jon Weidanz and Debra Weidanz in 2015 and is headquartered in Arlington, TX. | Oprichter | 01-01-2015 |
Eerdere bekende functies van Jon Weidanz
| Bedrijven | Functie | Einde |
|---|---|---|
MHC Biologics LLC
 MHC Biologics LLC BiotechnologyHealth Technology MHC Biologics, LLC, an emerging biotechnology company, has developed a unique and proprietary portfolio of breakthrough technologies that can be used in the development and design of novel therapeutics, including therapeutic vaccines for cancer and other diseases. MHC Biologics has been founded to focus on clinical applications of a suite of immunology tools developed in the laboratories of Dr. Jon Weidanz, Texas Tech University Pharmacy School and Receptor Logic, Ltd., and Dr. William Hildebrand, Oklahoma University Health Science Center and Pure Vaccine Solutions, LLC. These technology 'tools' can be utilized for immunology-based cancer diagnosis and treatment. Funded and managed by life sciences venture firm, Emergent Technologies, Inc., MHC Biologics is actively seeking commercialization partners. MHC Biologics offers breakthrough therapeutic antibody technology targeting a new class of disease biomarkers - peptides presented by the Major Histocompatibility Complex (MHC; also known as human leukocyte antigen, or HLA). These peptides are derived from intracellular processing of tumor or viral proteins and are presented as complexes with MHC proteins on antigen-presenting cells. MHC Biologics' unique antibody strategy exhibits disease-specific binding and efficacy in preclinical studies as a cancer therapeutic modality, providing next-generation products for treatment of cancer and other important diseases. | Oprichter | - |
| Baxter Diagnostics, Inc. | Corporate Officer/Principal | - |
| Texas Tech University | Corporate Officer/Principal | - |
Sunol Molecular Corp.
 Sunol Molecular Corp. Pharmaceuticals: MajorHealth Technology Part of ImmunityBio, Inc., Sunol Molecular Corp. is a company that develops gel therapeutics to treat disorders associated with the human tissue factor. The company is based in Miramar, FL. The company was founded by Hing C. Wong, Jon Weidanz, Peter R. Rhode. Sunol Molecular was acquired by Altor BioScience Corp., part of ImmunityBio, Inc. from August 01, 2017 on March 25, 2005. | Oprichter | - |
Receptor Logic, Inc.
 Receptor Logic, Inc. Pharmaceuticals: MajorHealth Technology Receptor Logic, Inc. provides a novel solution for the treatment of infectious diseases and cancers. The company was founded by Jon Weidanz in 2003 and is headquartered in Austin, TX. | Oprichter | - |
Opleiding van Jon Weidanz
| West Virginia University | Undergraduate Degree |
| The University of Alabama at Birmingham | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 5 |
|---|---|
Receptor Logic, Inc.
Receptor Logic, Inc. Pharmaceuticals: MajorHealth Technology Receptor Logic, Inc. provides a novel solution for the treatment of infectious diseases and cancers. The company was founded by Jon Weidanz in 2003 and is headquartered in Austin, TX. | Health Technology |
Sunol Molecular Corp.
Sunol Molecular Corp. Pharmaceuticals: MajorHealth Technology Part of ImmunityBio, Inc., Sunol Molecular Corp. is a company that develops gel therapeutics to treat disorders associated with the human tissue factor. The company is based in Miramar, FL. The company was founded by Hing C. Wong, Jon Weidanz, Peter R. Rhode. Sunol Molecular was acquired by Altor BioScience Corp., part of ImmunityBio, Inc. from August 01, 2017 on March 25, 2005. | Health Technology |
| Baxter Diagnostics, Inc. | |
MHC Biologics LLC
MHC Biologics LLC BiotechnologyHealth Technology MHC Biologics, LLC, an emerging biotechnology company, has developed a unique and proprietary portfolio of breakthrough technologies that can be used in the development and design of novel therapeutics, including therapeutic vaccines for cancer and other diseases. MHC Biologics has been founded to focus on clinical applications of a suite of immunology tools developed in the laboratories of Dr. Jon Weidanz, Texas Tech University Pharmacy School and Receptor Logic, Ltd., and Dr. William Hildebrand, Oklahoma University Health Science Center and Pure Vaccine Solutions, LLC. These technology 'tools' can be utilized for immunology-based cancer diagnosis and treatment. Funded and managed by life sciences venture firm, Emergent Technologies, Inc., MHC Biologics is actively seeking commercialization partners. MHC Biologics offers breakthrough therapeutic antibody technology targeting a new class of disease biomarkers - peptides presented by the Major Histocompatibility Complex (MHC; also known as human leukocyte antigen, or HLA). These peptides are derived from intracellular processing of tumor or viral proteins and are presented as complexes with MHC proteins on antigen-presenting cells. MHC Biologics' unique antibody strategy exhibits disease-specific binding and efficacy in preclinical studies as a cancer therapeutic modality, providing next-generation products for treatment of cancer and other important diseases. | Health Technology |
Abexxa Biologics, Inc.
Abexxa Biologics, Inc. Pharmaceuticals: MajorHealth Technology AbeXXa Biologics, Inc. is engaged in biopharmaceutical services. The company was founded by Jon Weidanz and Debra Weidanz in 2015 and is headquartered in Arlington, TX. | Health Technology |
